{"id":"fluorometholone","rwe":[{"pmid":"41858974","year":"2026","title":"Short-Term Intraocular Pressure Changes After 0.1% Fluorometholone in Pediatric Strabismus Surgery.","finding":"","journal":"Clinical ophthalmology (Auckland, N.Z.)","studyType":"Clinical Study"},{"pmid":"41781183","year":"2026","title":"Treating socket discharge and discomfort: a crossover randomised trial of vitamin A ointment, low-dose steroid eyedrops and artificial tears.","finding":"","journal":"The British journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"41704682","year":"2026","title":"Case Report: Conservative management of herpes simplex keratitis with corneal perforation and anterior chamber collapse.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"},{"pmid":"41608109","year":"2026","title":"Microsporidium Keratitis After Hurricane Francine: A Case Report.","finding":"","journal":"Case reports in ophthalmological medicine","studyType":"Clinical Study"},{"pmid":"41539314","year":"2026","title":"Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia.","finding":"","journal":"The Lancet. Global health","studyType":"Clinical Study"}],"_fda":{"id":"2bed0334-e39e-c18b-e063-6294a90af598","set_id":"19918ea5-8568-44d6-b8ee-7b2197cee85c","openfda":{"upc":["0371776100059","0371776100035"],"unii":["9I50C3I3OK"],"route":["OPHTHALMIC"],"rxcui":["1249629","1249631"],"spl_id":["2bed0334-e39e-c18b-e063-6294a90af598"],"brand_name":["Flarex"],"spl_set_id":["19918ea5-8568-44d6-b8ee-7b2197cee85c"],"package_ndc":["71776-100-05","71776-100-03"],"product_ndc":["71776-100"],"generic_name":["FLUOROMETHOLONE ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLUOROMETHOLONE ACETATE"],"manufacturer_name":["Eyevance Pharmaceuticals"],"application_number":["NDA019079"],"is_original_packager":[true]},"version":"7","warnings":["WARNINGS FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION. Use in the treatment of herpes simplex infection requires great caution. Prolonged use may result in glaucoma, damage to the optic nerve, defect in visual acuity and visual field, cataract formation and/or may aid in the establishment of secondary ocular infections from pathogens due to suppression of host response. Acute purulent infections of the eye may be masked or exacerbated by presence of steroid medication. Topical ophthalmic corticosteroids may slow corneal wound healing. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids. If these products are used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients."],"pregnancy":["Pregnancy Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed. There are no adequate and well controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"description":["DESCRIPTION FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% is a corticosteroid prepared as a sterile topical ophthalmic suspension. The active ingredient, fluorometholone acetate, is a white to creamy white powder with an empirical formula of C 24 H 31 FO 5 and a molecular weight of 418.5. Its chemical name is 9-fluoro-11β, 17-dihydroxy-6α-methylpregna-1, 4-diene-3, 20-dione 17-acetate. The chemical structure of Fluorometholone Acetate is presented below: Each mL of FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% contains: Active: fluorometholone acetate 1 mg (0.1%). Preservative: benzalkonium chloride 0.01%. Inactives: sodium chloride, monobasic sodium phosphate, edetate disodium, hydroxyethyl cellulose, tyloxapol, hydrochloric acid and/or sodium hydroxide (to adjust pH), and purified water. The pH of the suspension is approximately 7.3, with an osmolality of approximately 300 mOsm/kg. Chemical Structure"],"precautions":["PRECAUTIONS General Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Prescription Guidelines The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation. Information for Patients Do not touch dropper tip to any surface, as this may contaminate the suspension. The preservative in FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% but may be reinserted 15 minutes after instillation. Patients should be advised that their vision may be temporarily blurred following dosing with FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%. Care should be exercised in operating machinery or driving a motor vehicle. Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the possibility of these effects with fluorometholone. Pregnancy Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed. There are no adequate and well controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"how_supplied":["HOW SUPPLIED FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is supplied in white low density polyethylene (LDPE) bottles, with natural LDPE dispensing plugs and pink polypropylene closures. The product is supplied as 5 mL in an 8 mL bottle. 5 mL: NDC 71776-100-05 STORAGE Store upright between 2°C to 25°C (36°F to 77°F). After opening, FLAREX can be used until the expiration date on the bottle. Protect from freezing."],"geriatric_use":["Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20250117","nursing_mothers":["Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLAREX (fluorometholone acetate ophthalmic suspension) 0.1%, is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur. Postmarketing Experience The following reaction has been identified during post-marketing use of FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1% in clinical practice. Because reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reaction, which has been chosen for inclusion due to either its seriousness, frequency of reporting, possible causal connection to FLAREX, or a combination of these factors, includes: dysgeusia. The following rare adverse reactions have been reported: Cushing's syndrome and adrenal suppression may occur after very frequent use of topical ophthalmic corticosteroids, particularly in very young children."],"contraindications":["CONTRAINDICATIONS Contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation."],"how_supplied_table":["<table width=\"85%\" styleCode=\"Noautorules\"><colgroup><col align=\"left\" valign=\"top\" width=\"50%\"/><col align=\"left\" valign=\"top\" width=\"50%\"/></colgroup><tbody><tr><td>5 mL:</td><td>NDC 71776-100-05</td></tr><tr><td/><td/></tr></tbody></table>"],"general_precautions":["General Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use."],"teratogenic_effects":["Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed. There are no adequate and well controlled studies of fluorometholone in pregnant women, and it is not known whether fluorometholone can cause fetal harm when administered to a pregnant woman. Fluorometholone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"storage_and_handling":["STORAGE Store upright between 2°C to 25°C (36°F to 77°F). After opening, FLAREX can be used until the expiration date on the bottle. Protect from freezing."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. Corticosteroids cause a rise in intraocular pressure (IOP) in susceptible individuals. In a small study, FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% demonstrated a significantly longer average time to produce a rise in IOP than did dexamethasone phosphate; however, the ultimate magnitude of the rise was equivalent for both drugs and in a small percentage of individuals a significant rise in IOP occurred within three days."],"indications_and_usage":["INDICATIONS AND USAGE FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye."],"information_for_patients":["Information for Patients Do not touch dropper tip to any surface, as this may contaminate the suspension. The preservative in FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% but may be reinserted 15 minutes after instillation. Patients should be advised that their vision may be temporarily blurred following dosing with FLAREX ® (fluorometholone acetate ophthalmic suspension) 0.1%. Care should be exercised in operating machinery or driving a motor vehicle."],"spl_unclassified_section":["Manufactured for: Eyevance Pharmaceuticals, LLC Fort Worth, TX 76102 USA Revised: 7/2022"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Shake Well Before Using. One to two drops instilled into the conjunctival sac(s) four times daily. During the initial 24 to 48 hours the dosage may be safely increased to two drops every two hours. If no improvement after two weeks, consult physician. Care should be taken not to discontinue therapy prematurely. Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation [see PRECAUTIONS ] ."],"spl_product_data_elements":["Flarex fluorometholone acetate BENZALKONIUM CHLORIDE SODIUM CHLORIDE SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM EDETATE DISODIUM HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%) TYLOXAPOL HYDROCHLORIC ACID SODIUM HYDROXIDE WATER FLUOROMETHOLONE ACETATE FLUOROMETHOLONE"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Carton Sample - Not for Sale eyevance ® pharmaceuticals Flarex ® (fluorometholone acetate ophthalmic suspension) 0.1 % FOR TOPICAL OPHTHALMIC USE 2.5mL Sterile 2.5 mL PRINCIPAL DISPLAY PANEL - 2.5 mL Bottle Carton","PRINCIPAL DISPLAY PANEL - 5 mL Bottle Carton eyevance ™ pharmaceuticals Flarex ® (fluorometholone acetate ophthalmic suspension) 0.1 % FOR TOPICAL OPHTHALMIC USE 5 mL Sterile 5 mL PRINCIPAL DISPLAY PANEL - 5 mL Bottle Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No studies have been conducted in animals or in humans to evaluate the possibility of these effects with fluorometholone."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"C05AA06","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Ointment","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Suspension/ Drops","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Corneal abrasion","category":"indication"},{"label":"Corneal ulcer","category":"indication"},{"label":"Cyclitis","category":"indication"},{"label":"Herpes zoster keratitis","category":"indication"},{"label":"Iridocyclitis","category":"indication"},{"label":"Abbvie","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Glucocorticoids","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"TREATMENT FAILURE","source":"FDA FAERS","actionTaken":"352 reports"},{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"269 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"240 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"226 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"212 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"190 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"186 reports"},{"date":"","signal":"EYE IRRITATION","source":"FDA FAERS","actionTaken":"183 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"163 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"156 reports"}],"commonSideEffects":[{"effect":"Delayed wound healing","drugRate":"reported","severity":"unknown"},{"effect":"Systemic hypercorticoidism","drugRate":"reported","severity":"unknown"},{"effect":"Acute anterior uveitis","drugRate":"reported","severity":"unknown"},{"effect":"Perforation of the globe","drugRate":"reported","severity":"unknown"},{"effect":"Keratitis","drugRate":"reported","severity":"unknown"},{"effect":"Conjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"Corneal ulcers","drugRate":"reported","severity":"unknown"},{"effect":"Mydriasis","drugRate":"reported","severity":"unknown"},{"effect":"Conjunctival hyperemia","drugRate":"reported","severity":"unknown"},{"effect":"Loss of accommodation","drugRate":"reported","severity":"unknown"},{"effect":"Ptosis","drugRate":"reported","severity":"unknown"},{"effect":"Secondary ocular infection","drugRate":"reported","severity":"unknown"},{"effect":"Allergic reactions","drugRate":"reported","severity":"unknown"},{"effect":"Foreign body sensation","drugRate":"reported","severity":"unknown"},{"effect":"Erythema of eyelid","drugRate":"reported","severity":"unknown"},{"effect":"Eyelid edema/eye swelling","drugRate":"reported","severity":"unknown"},{"effect":"Eye discharge","drugRate":"reported","severity":"unknown"},{"effect":"Eye pain","drugRate":"reported","severity":"unknown"},{"effect":"Eye pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Lacrimation increased","drugRate":"reported","severity":"unknown"},{"effect":"Ocular irritation","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Taste perversion","drugRate":"reported","severity":"unknown"},{"effect":"Visual disturbance (blurry vision)","drugRate":"reported","severity":"unknown"},{"effect":"Visual field defect","drugRate":"reported","severity":"unknown"},{"effect":"Posterior subcapsular cataract formation","drugRate":"reported","severity":"unknown"},{"effect":"Elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of cornea and conjunctiva.","Mycobacterial infection of the eye.","Fungal diseases of the eye.","Acute purulent untreated infections.","Known hypersensitivity to any component of this preparation."],"specialPopulations":{"Pregnancy":"Fluorometholone has been shown to be embryocidal and teratogenic in rabbits when administered at low multiples of the human ocular dose. Fluorometholone was applied ocularly to rabbits daily on days 6-18 of gestation, and dose-related fetal loss and fetal abnormalities including cleft palate, deformed rib cage, anomalous limbs and neural abnormalities such as encephalocele, craniorachischisis, and spina bifida were observed. There are no adequate and well-controlled studies in pregnant women. Use in pregnant women only if clearly needed.","Geriatric use":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","Paediatric use":"Safety and effectiveness in infants below the age of two years have not been established."}},"trials":[],"aliases":[],"company":"AbbVie","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$15.4158/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$5,550","description":"FLUOROMETHOLONE 0.1% DROPS","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T15:38:33.933264","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUOROMETHOLONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:05.547163+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:13.021045+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:31:04.183299+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOROMETHOLONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:13.859158+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:01.014024+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:27.434282+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:01.014086+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:31:15.379647+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocorticoid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:14.465085+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200600/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:14.347313+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:21.955518+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA019079","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:31:01.014097+00:00"}},"allNames":"fml","offLabel":[],"synonyms":["fluorometholone","fluormetholon","flumetholone","flumetholon"],"timeline":[{"date":"1972-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ALLERGAN to Abbvie"},{"date":"1982-07-28","type":"positive","source":"FDA Orange Book","milestone":"Fml approved — 0.1%"},{"date":"1985-09-04","type":"positive","source":"FDA Orange Book","milestone":"Fml approved — 0.1%"},{"date":"1986-04-23","type":"positive","source":"FDA Orange Book","milestone":"Fml Forte approved — 0.25%"},{"date":"2026-02-12","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Fml (FLUOROMETHOLONE) is a corticosteroid medication developed by Allergan and currently owned by Abbvie. It targets the glucocorticoid receptor to reduce inflammation in the eye. Fml is approved to treat various ocular conditions, including allergic conjunctivitis, corneal abrasions, and post-operative ocular inflammation. The medication is available as a generic product, off-patent, with multiple manufacturers. Key safety considerations include potential increased intraocular pressure and cataract formation.","approvals":[{"date":"1972-01-12","orphan":false,"company":"ALLERGAN","regulator":"FDA"}],"brandName":"Fml","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Corneal abrasion","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"bacitracin","slug":"bacitracin","company":"Pharmacia And Upjohn"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null},{"indication":"Corneal ulcer","otherDrugs":[{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fluorometholone acetate","slug":"fluorometholone-acetate","company":"Alcon"},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Cyclitis","otherDrugs":[{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fluorometholone acetate","slug":"fluorometholone-acetate","company":"Alcon"},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":40000},{"indication":"Herpes zoster keratitis","otherDrugs":[{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fluorometholone acetate","slug":"fluorometholone-acetate","company":"Alcon"},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Iridocyclitis","otherDrugs":[{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fluorometholone acetate","slug":"fluorometholone-acetate","company":"Alcon"},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":40000},{"indication":"Iritis","otherDrugs":[{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"fluorometholone acetate","slug":"fluorometholone-acetate","company":"Alcon"},{"name":"hydrocortisone","slug":"hydrocortisone","company":"Merck"}],"globalPrevalence":null},{"indication":"Post-Op Ocular Inflammation","otherDrugs":[{"name":"benzalkonium","slug":"benzalkonium","company":""},{"name":"bromfenac","slug":"bromfenac","company":"Bausch And Lomb Inc"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"dexamethasone","slug":"dexamethasone","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid","explanation":"","oneSentence":"","technicalDetail":"Fml is a small molecule corticosteroid that binds to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of genes involved in inflammation. By binding to GR, Fml inhibits the transcription of pro-inflammatory genes, leading to a decrease in the production of inflammatory cytokines and mediators, and ultimately reducing inflammation in the eye."},"commercial":{"launchDate":"1972","_launchSource":"DrugCentral (FDA 1972-01-12, ALLERGAN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1208","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUOROMETHOLONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOROMETHOLONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:32:36.746813","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:28.016117+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"prednisolone","drugSlug":"prednisolone","fdaApproval":"1955-06-21","genericCount":42,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluocinolone acetonide","drugSlug":"fluocinolone-acetonide","fdaApproval":"1963-02-15","patentExpiry":"Nov 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fluocinonide","drugSlug":"fluocinonide","fdaApproval":"1971-06-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"triamcinolone","drugSlug":"triamcinolone","fdaApproval":"1957-12-03","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"fluorometholone","indications":{"approved":[{"id":"fluorometholone-steroid-responsive-ocular-infl","name":"Steroid-responsive ocular inflammation","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with steroid responsive inflammatory conditions of the eye","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with steroid responsive inflammatory conditions of the eye","diagnosticRequired":null,"brandNameForIndication":"Fml"}],"offLabel":[{"name":"Allergic otitis externa","source":"DrugCentral","drugName":"FLUOROMETHOLONE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Otitis Externa Eczema","source":"DrugCentral","drugName":"FLUOROMETHOLONE"},{"name":"Otitis Externa Seborrhea","source":"DrugCentral","drugName":"FLUOROMETHOLONE"},{"name":"Otitis externa","source":"DrugCentral","drugName":"FLUOROMETHOLONE"}],"pipeline":[]},"_fixedFields":["pubmed(407)"],"currentOwner":"Abbvie","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-class"},{"drugId":"prednisolone","brandName":"prednisolone","genericName":"prednisolone","approvalYear":"1955","relationship":"same-class"},{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-class"},{"drugId":"fluocinolone-acetonide","brandName":"fluocinolone acetonide","genericName":"fluocinolone acetonide","approvalYear":"1963","relationship":"same-class"},{"drugId":"fluocinonide","brandName":"fluocinonide","genericName":"fluocinonide","approvalYear":"1971","relationship":"same-class"},{"drugId":"triamcinolone","brandName":"triamcinolone","genericName":"triamcinolone","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":["Trachomatous Trichiasis (TT)","Eye Diseases","Eyelid Diseases","Trachomatous","Trichiasis"],"enrollment":2410,"completionDate":"2024-11-30"},{"nctId":"NCT07308938","phase":"PHASE2","title":"Fluorometholone Study","status":"NOT_YET_RECRUITING","sponsor":"Vishal Jhanji","startDate":"2026-03-31","conditions":["Keratitis Bacterial","Corneal Ulcer (Diagnosis)"],"enrollment":174,"completionDate":"2030-12-31"},{"nctId":"NCT05716945","phase":"PHASE4","title":"The OPTIMISE Study","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2024-07-29","conditions":["Pseudophakic Bullous Keratopathy","Fuchs' Endothelial Dystrophy","Intraocular Pressure"],"enrollment":342,"completionDate":"2029-03"},{"nctId":"NCT06876116","phase":"PHASE4","title":"Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":["Dry Eye Disease (DED)"],"enrollment":32,"completionDate":"2024-05-24"},{"nctId":"NCT06498440","phase":"PHASE4","title":"Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-09-01","conditions":["Open Angle Glaucoma","Ocular Hypertension","Postoperative Inflammation"],"enrollment":126,"completionDate":"2025-07-01"},{"nctId":"NCT06209879","phase":"PHASE4","title":"Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-02-05","conditions":["Dry Eye Syndromes"],"enrollment":40,"completionDate":"2024-12"},{"nctId":"NCT04839549","phase":"PHASE4","title":"Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea","status":"WITHDRAWN","sponsor":"Eye Associates of Central Texas","startDate":"2020-06-06","conditions":["Ocular Rosacea"],"enrollment":0,"completionDate":"2022-11-29"},{"nctId":"NCT05771194","phase":"PHASE4","title":"Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2021-02-01","conditions":["Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid"],"enrollment":40,"completionDate":"2022-07-02"},{"nctId":"NCT05587231","phase":"PHASE4","title":"Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK","status":"UNKNOWN","sponsor":"Navy Medical Center San Diego","startDate":"2022-10","conditions":["Steroid Ophthalmic Insert"],"enrollment":60,"completionDate":"2024-10"},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":["Corneal Epithelial Wound"],"enrollment":250,"completionDate":"2022-09"},{"nctId":"NCT02030990","phase":"PHASE2,PHASE3","title":"The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements","status":"UNKNOWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2014-08","conditions":["Corneal Opacity"],"enrollment":300,"completionDate":"2023-07"},{"nctId":"NCT05313828","phase":"","title":"Effect of Various Treatment Modalities on Dendritic Vial Ulcer","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-03-18","conditions":["Corneal Ulcer"],"enrollment":40,"completionDate":"2022-07-20"},{"nctId":"NCT05131152","phase":"NA","title":"Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-12-01","conditions":["Dry Eye"],"enrollment":100,"completionDate":"2024-05"},{"nctId":"NCT05011916","phase":"PHASE1,PHASE2","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-08-10","conditions":["Corneal Neovascularization"],"enrollment":60,"completionDate":"2022-08-09"},{"nctId":"NCT03123614","phase":"PHASE4","title":"Loteprednol vs. Prednisolone and Fluorometholone","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-19","conditions":["Intraocular Pressure","Corneal Opacity"],"enrollment":131,"completionDate":"2018-07"},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":["Adenoviral Keratoconjunctivitis"],"enrollment":51,"completionDate":"2019-04-01"},{"nctId":"NCT04117698","phase":"PHASE3","title":"Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-01","conditions":["Uveitis, Anterior"],"enrollment":116,"completionDate":"2023-05-01"},{"nctId":"NCT03747614","phase":"PHASE4","title":"Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2017-06-30","conditions":["Dry Eye Syndromes","Inflammation","Microvessels"],"enrollment":20,"completionDate":"2020-06-30"},{"nctId":"NCT01189864","phase":"","title":"Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2010-02-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":3493,"completionDate":"2017-02-03"},{"nctId":"NCT01024322","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-10-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":1189,"completionDate":"2017-02-03"},{"nctId":"NCT01097447","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-12-01","conditions":["Keratoconus","Ectasia","Degeneration"],"enrollment":2619,"completionDate":"2017-04-30"},{"nctId":"NCT02974387","phase":"PHASE4","title":"Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study","status":"UNKNOWN","sponsor":"Dr Salouti Eye Research Center","startDate":"2017-04","conditions":["Must be PRK Candidate"],"enrollment":200,"completionDate":"2017-11"},{"nctId":"NCT02816905","phase":"PHASE4","title":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-10","conditions":["Intraocular Pressure"],"enrollment":40,"completionDate":"2016-06"},{"nctId":"NCT01949454","phase":"NA","title":"Fluorometholone as Ancillary Therapy for TT Surgery","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-11","conditions":["Trichiasis","Trachoma","Bilamellar Tarsal Rotation"],"enrollment":154,"completionDate":"2016-04"},{"nctId":"NCT02051023","phase":"PHASE3","title":"Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2014-02","conditions":["Dry Eye"],"enrollment":41,"completionDate":"2014-12"},{"nctId":"NCT01448213","phase":"PHASE2","title":"Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)","status":"COMPLETED","sponsor":"Price Vision Group","startDate":"2011-10","conditions":["Fuchs' Dystrophy","Bullous Keratopathy"],"enrollment":264,"completionDate":"2014-01"},{"nctId":"NCT02218827","phase":"NA","title":"Topical Steroid Treatment For Dry Eye","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2014-09","conditions":["Dry Eye"],"enrollment":30,"completionDate":"2015-09"},{"nctId":"NCT02147509","phase":"NA","title":"Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome","status":"COMPLETED","sponsor":"Jinyang Li","startDate":"2013-03","conditions":["Sjögren's Syndrome Patients With Severe Dry Eye"],"enrollment":64,"completionDate":"2014-04"},{"nctId":"NCT02011776","phase":"","title":"A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome","status":"COMPLETED","sponsor":"Santen Pharmaceutical(China) Co.,LTD","startDate":"2013-03","conditions":["Dry Eye Syndromes","Sjögren Syndrome"],"enrollment":35,"completionDate":"2013-11"},{"nctId":"NCT01682421","phase":"NA","title":"Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation","status":"WITHDRAWN","sponsor":"Aarhus University Hospital","startDate":"2012-09","conditions":["Endothelial Dystrophy","Secondary Bullous Keratopathy","Posterior Lamellar Keratoplasty","Descemet's Stripping Endothelial Keratoplasty"],"enrollment":0,"completionDate":""},{"nctId":"NCT01562795","phase":"NA","title":"Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Wenzhou Medical University","startDate":"2012-03","conditions":["Moderate to Severe Dry Eye Syndrome"],"enrollment":48,"completionDate":"2012-07"},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":["Epiphora"],"enrollment":0,"completionDate":""},{"nctId":"NCT01288404","phase":"NA","title":"Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2008-01","conditions":["Pterygium of the Conjunctiva and Cornea"],"enrollment":80,"completionDate":"2010-11"},{"nctId":"NCT00707421","phase":"PHASE3","title":"Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2005-07","conditions":["Glaucoma","Trabeculectomy","Fibrosis","Intraocular Pressure"],"enrollment":62,"completionDate":"2009-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Ointment, Solution/ Drops, Suspension/ Drops","formulations":[{"form":"OINTMENT","route":"OPHTHALMIC","productName":"FML"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"FLUOROMETHOLONE"},{"form":"SUSPENSION/ DROPS","route":"OPHTHALMIC","productName":"FML"},{"form":"SUSPENSION/ DROPS","route":"OPHTHALMIC","productName":"FML FORTE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146545","MMSL":"4744","NDDF":"002194","UNII":"SV0CSG527L","VUID":"4018212","CHEBI":"CHEBI:31625","VANDF":"4018212","INN_ID":"803","RXNORM":"4491","UMLSCUI":"C0016351","chemblId":"CHEMBL1200600","ChEMBL_ID":"CHEMBL1200600","KEGG_DRUG":"D01367","DRUGBANK_ID":"DB00324","PUBCHEM_CID":"9878","SNOMEDCT_US":"108851006","IUPHAR_LIGAND_ID":"7079","MESH_DESCRIPTOR_UI":"D005469"},"formularyStatus":[],"originalProduct":{"form":"OINTMENT","route":"OPHTHALMIC","company":"Allergan, Inc.","brandName":"FML","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1972-","companyName":"Allergan","relationship":"Original Developer"},{"period":"present","companyName":"Abbvie","relationship":"Current Owner"}],"publicationCount":408,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"C05AA06","allCodes":["C05AA06","D07AB06","D07CB03","D07XB04","D10AA01","S01BA07","S01BB03","S01CA07","S01CB05"]},"biosimilarFilings":[],"originalDeveloper":"Allergan","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Amneal","Difgen Pharms","Novartis"],"status":"approved","companyName":"Abbvie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"1972","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1972-01-12T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-11-05T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":"NDA019216"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-06-08T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":"NDA016851"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-04-21T00:00:00.000Z","mah":"HARROW EYE","brand_name_local":null,"application_number":"NDA019079"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-01-09T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA216348"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-12T00:00:00.000Z","mah":"DIFGEN PHARMS","brand_name_local":null,"application_number":"ANDA218819"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:31:28.016117+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}